Cargando…

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia

SIMPLE SUMMARY: Chronic lymphocytic leukemia (CLL) represents the most frequent B cell malignancy in Western countries and still remains as an incurable disease. Despite recent advances in targeted therapies including ibrutinib, idelalisib or venetoclax, resistance mechanisms have been described and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sordo-Bahamonde, Christian, Lorenzo-Herrero, Seila, Gonzalez-Rodriguez, Ana P, R. Payer, Ángel, González-García, Esther, López-Soto, Alejandro, Gonzalez, Segundo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067870/ https://www.ncbi.nlm.nih.gov/pubmed/33917094 http://dx.doi.org/10.3390/cancers13081766

Ejemplares similares

BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
por: Villa-Álvarez, Mónica, et al.
Publicado: (2018)

LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

Mechanisms of Resistance to NK Cell Immunotherapy
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2020)

NK Cell-Based Immunotherapy in Cancer Metastasis
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2018)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Increased BTLA and HVEM in gastric cancer are associated with progression and poor prognosis
por: Lan, Xiuwen, et al.
Publicado: (2017)

BTLA inhibition has a dominant role in the cis-complex of BTLA and HVEM
por: Battin, Claire, et al.
Publicado: (2022)

The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Immunosurveillance of cancer cell stress
por: Lorenzo-Herrero, Seila, et al.
Publicado: (2019)

Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression
por: Gonzalez-Rodriguez, Ana P., et al.
Publicado: (2020)

Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding
por: Spodzieja, Marta, et al.
Publicado: (2020)

A crucial role for HVEM and BTLA in preventing intestinal inflammation
por: Steinberg, Marcos W., et al.
Publicado: (2008)

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression
por: Wakeley, Michelle E., et al.
Publicado: (2023)

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
por: Demerlé, Clemence, et al.
Publicado: (2021)

Attenuation of the BTLA/HVEM Regulatory Network in the Circulation in Primary Sjögren’s Syndrome
por: Small, Annabelle, et al.
Publicado: (2022)

The BTLA–HVEM–CD5 Immunoregulatory Axis–An Instructive Mechanism Governing pTreg Cell Differentiation
por: Bourque, Jessica, et al.
Publicado: (2019)

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses
por: Spodzieja, Marta, et al.
Publicado: (2017)

BTLA/HVEM Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection
por: Yu, Xueping, et al.
Publicado: (2019)

HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160
por: Liu, Weifeng, et al.
Publicado: (2021)

Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease
por: Huergo-Zapico, Leticia, et al.
Publicado: (2014)

The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis
por: Mintz, Michelle A., et al.
Publicado: (2019)

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells
por: Acebes-Huerta, Andrea, et al.
Publicado: (2014)

The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
por: Yang, Bin, et al.
Publicado: (2016)

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
por: Demerlé, Clémence, et al.
Publicado: (2023)

Correction: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors
Publicado: (2023)

CD8 T Cell Memory to a Viral Pathogen Requires Trans Cosignaling between HVEM and BTLA
por: Flynn, Rachel, et al.
Publicado: (2013)

Correction: The Expression of LIGHT Was Increased and the Expression of HVEM and BTLA Were Decreased in the T Cells of Patients with Rheumatoid Arthritis
por: Yang, Bin, et al.
Publicado: (2017)

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies
por: Kuncewicz, Katarzyna, et al.
Publicado: (2020)

The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota
por: Kou, Yanbo, et al.
Publicado: (2022)

The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure
por: Xu, Huan, et al.
Publicado: (2012)

Distinct Changes of BTLA and HVEM Expressions in Circulating CD4(+) and CD8(+) T Cells in Hepatocellular Carcinoma Patients
por: Liu, Jiayu, et al.
Publicado: (2018)

Allosteric regulation of binding specificity of HVEM for CD160 and BTLA ligands upon G89F mutation
por: Shrestha, Rojan, et al.
Publicado: (2021)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Lenalidomide and Chronic Lymphocytic Leukemia
por: González-Rodríguez, Ana Pilar, et al.
Publicado: (2013)

BTLA Interaction with HVEM Expressed on CD8(+) T Cells Promotes Survival and Memory Generation in Response to a Bacterial Infection
por: Steinberg, Marcos W., et al.
Publicado: (2013)

Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients
por: Wang, Zijie, et al.
Publicado: (2017)

Immunoglobulin‐like transcript 2 blockade restores antitumor immune responses in glioblastoma
por: Lorenzo‐Herrero, Seila, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhj4ukdpb4md46s95uhs6lo95g